SAN FRANCISCO, Aug. 7 - Lion Bioscience today reported a decrease in first-quarter revenue on top of expanding net losses.
Total revenue in the quarter ended June 30 decreased to €7.5 million, or roughly $7.3 million, from €8.9 million in the year-ago period, Lion said.
Net loss for the quarter ballooned to €19.2 million, or €.97 per share, from €11.2 million, or €.60 per share, one year ago. The company attributed increased losses to costs integrating NetGenics, acquired in January, as well as a year-over-year drop in revenue.
The company did register an increase in revenue from software licenses, CEO Friedrich von Bohlen said in a statement.
R&D costs increased to €11.6 million for the quarter ended June 30 compared to €10.1 million for the year-ago period.
Lion said it had €37.4 million cash and cash equivalents as of June 30. The company had €66.4 million in short-term marketable securities at the end of the first quarter compared to €104.8 million as of
Click here for more information.